Cargando…

An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia

Biomarkers from multiple modalities have been shown to correlate with cognition in Parkinson’s disease (PD) and in Alzheimer’s disease (AD). However, the relationships of these markers with each other, and the use of multiple markers in concert to predict an outcome of interest, are areas that are m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berlyand, Yosef, Weintraub, Daniel, Xie, Sharon X., Mellis, Ian A., Doshi, Jimit, Rick, Jacqueline, McBride, Jennifer, Davatzikos, Christos, Shaw, Leslie M., Hurtig, Howard, Trojanowski, John Q., Chen-Plotkin, Alice S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727929/ https://www.ncbi.nlm.nih.gov/pubmed/26812251 http://dx.doi.org/10.1371/journal.pone.0147319

Ejemplares similares

Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia
por: Akhtar, Rizwan S., et al.
Publicado: (2017)

Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson’s Disease
por: Gallagher, Julia, et al.
Publicado: (2021)

Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype
por: Cooper, Christine A., et al.
Publicado: (2016)

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
por: Lim, Nicholas S., et al.
Publicado: (2016)

White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration
por: Kandel, Benjamin M., et al.
Publicado: (2016)

Genetic prediction of impulse control disorders in Parkinson's disease
por: Weintraub, Daniel, et al.
Publicado: (2022)

Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases
por: Sheinerman, Kira S., et al.
Publicado: (2017)

Characterization of Parkinson’s disease using blood-based biomarkers: A multicohort proteomic analysis
por: Posavi, Marijan, et al.
Publicado: (2019)

Diagnostic potential of structural neuroimaging for depression from a multi-ethnic community sample
por: Sankar, Anjali, et al.
Publicado: (2016)

Leveraging machine learning predictive biomarkers to augment the statistical power of clinical trials with baseline magnetic resonance imaging
por: Lou, Carolyn, et al.
Publicado: (2021)

Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI
por: Toledo, Jon B., et al.
Publicado: (2013)

Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers()()
por: Da, Xiao, et al.
Publicado: (2013)

Diagnosis and management of Parkinson's disease dementia
por: Poewe, W, et al.
Publicado: (2008)

Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
por: Sandelius, Åsa, et al.
Publicado: (2018)

Bile Acids in Dementia: Brain Amyloid, White Matter Lesions, and Atrophy
por: Varma, Vijay, et al.
Publicado: (2020)

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
por: Toledo, Jon B, et al.
Publicado: (2013)

A deep learning framework identifies dimensional representations of Alzheimer’s Disease from brain structure
por: Yang, Zhijian, et al.
Publicado: (2021)

Sex differences in the association between amyloid and longitudinal brain volume change in cognitively normal older adults
por: Armstrong, Nicole M., et al.
Publicado: (2019)

Regional tract-specific white matter hyperintensities are associated with patterns of aging-related brain atrophy via vascular risk factors, but also independently
por: Habes, Mohamad, et al.
Publicado: (2018)

Plasma phosphorylated tau181 predicts cognitive and functional decline
por: Tropea, Thomas F., et al.
Publicado: (2022)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Woman with atraumatic violaceous thigh discoloration
por: Berlyand, Yosef, et al.
Publicado: (2020)

Neuroanatomical Classification in a Population-Based Sample of Psychotic Major Depression and Bipolar I Disorder with 1 Year of Diagnostic Stability
por: Serpa, Mauricio H., et al.
Publicado: (2014)

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated
por: Robinson, John L, et al.
Publicado: (2023)

Validating virtual administration of neuropsychological testing in Parkinson disease: a pilot study
por: Weintraub, Daniel, et al.
Publicado: (2023)

Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline
por: Zuroff, Leah, et al.
Publicado: (2022)

T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease
por: Haris, Mohammad, et al.
Publicado: (2015)

Validating virtual administration of neuropsychological testing in Parkinson disease: a pilot study
por: Gallagher, Julia, et al.
Publicado: (2023)

Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging
por: Abner, Erin L., et al.
Publicado: (2016)

Disentangling Alzheimer’s disease neurodegeneration from typical brain ageing using machine learning
por: Hwang, Gyujoon, et al.
Publicado: (2022)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Multimodal Magnetic Resonance Imaging Study of Treatment-Naïve Adults with Attention-Deficit/Hyperactivity Disorder
por: Chaim, Tiffany M., et al.
Publicado: (2014)

Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
por: Kang, Ju-Hee, et al.
Publicado: (2014)

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
por: Blennow, Kaj, et al.
Publicado: (2019)

The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders
por: Irwin, David J., et al.
Publicado: (2018)

Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
por: Toledo, Jon B, et al.
Publicado: (2014)

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease
por: Cousins, Katheryn A. Q., et al.
Publicado: (2023)

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology
por: Portelius, Erik, et al.
Publicado: (2018)

Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
por: Henderson, Michael X., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mdfdb66vifkm96sq1et1nl8om9